Session » SLE – Clinical Poster I: Epidemiology & Pathogenesis

Date: Sunday, November 10, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 646

A Meta-Analysis of Anti-Ribosomal P Autoantibodies in Systemic Lupus Erythematosus: A Misunderstood Autoantibody

9:00AM-11:00AM: Abstract Number: 641

A Novel Method to Analyze Circulating Immune Complexes Predicts Disease Activity and Severity in Systemic Lupus Erythematosus and Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 705

A Tale of Three Cohorts: SLE Criteria in Developed vs Developing Countries

9:00AM-11:00AM: Abstract Number: 691

Adjusted GAPSS in Systemic Lupus Erythematosus Patients in Argentina

9:00AM-11:00AM: Abstract Number: 674

Affordability Concerns Prevalent Among Patients with Systemic Lupus Erythematosus (SLE)

9:00AM-11:00AM: Abstract Number: 639

African-American Risk of Proteinuria After SLE Diagnosis Increases Throughout Thirty Years of Followup

9:00AM-11:00AM: Abstract Number: 660

Antiphospholipid Syndrome (APS) in Systemic Lupus Erythematosus (SLE) Leads to a More Severe Disease

9:00AM-11:00AM: Abstract Number: 654

Applying Systemic Lupus International Collaborating Clinics (SLICC) and Provisional ACR/EULAR Systemic Lupus Erythematosus Classification Criteria in a Cohort of Patients with Undifferentiated Connective Tissue Disease

9:00AM-11:00AM: Abstract Number: 655

Assessing Perceptions, Barriers, and Preferences to Exercise in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 670

Association Between Ambient Air Pollutant Exposures and Childhood-Onset Systemic Lupus Erythematosus: A 12-Year Population-Based Cohort Study in Taiwan

9:00AM-11:00AM: Abstract Number: 643

Association Between Neutrophil to Lymphocyte, Monocyte to Lymphocyte, and Platelet to Lymphocyte Ratios and Lupus Disease Activity and Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 686

Association Between the Soluble Terminal Complement Complex C5b-9 (sC5b-9) and Signs of Active Kidney Disease in a Swiss SLE Cohort

9:00AM-11:00AM: Abstract Number: 645

Association of Co-positivity for Anti-dsDNA, -Nucleosome, and -Histone Antibodies and Disease Activity in Patients with Lupus Nephritis: Results from the KORNET Registry

9:00AM-11:00AM: Abstract Number: 701

Association of Cumulative Urinary Podocyte Number and Urinary Podocalyxin with Long-term Renal Prognosis in Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 661

Association of Serum and Urine Levels of TWEAK, MCP-1 and NGAL with Disease Activity in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 683

Biologic Differences Between Type 1 and 2 Lupus

9:00AM-11:00AM: Abstract Number: 694

Body Mass Index at Time of Diagnosis Is Predictive of Future Disease Activity in SLE

9:00AM-11:00AM: Abstract Number: 687

CCP Autoantibody Positive SLE Patients Show Unique Enrichments in SLE Criteria and Autoantibody Biomarkers That Vary by Race

9:00AM-11:00AM: Abstract Number: 675

Clinical and Serological Lupus Activity Before and After Developing End Stage Renal Disease

9:00AM-11:00AM: Abstract Number: 684

Clinical Biomarkers at Renal Flare Are Associated with Histologic Changes in Repeat Renal Biopsy in Patients with Biopsy-proven Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 673

Clinical Characteristics of Lymphadenopathy in Systemic Lupus Erythematous: A Case Control Study from a Tertiary Care Center

9:00AM-11:00AM: Abstract Number: 652

Clinical Relevance According to Staining Patterns and Titers of Antinuclear Antibody

9:00AM-11:00AM: Abstract Number: 676

Cluster Profiling of Patients in a Real-World Data Set with Systemic Lupus Erythematosus and Their Associated Treatments

9:00AM-11:00AM: Abstract Number: 688

Comparison of the Physicians’ Clinical Diagnosis and the EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a Multiethnic Cohort

9:00AM-11:00AM: Abstract Number: 669

Complement Activation in Probable Systemic Lupus Erythematosus (pSLE) May Predict Progression to SLE Defined by Fulfillment of ACR Classification Criteria

9:00AM-11:00AM: Abstract Number: 642

Complement Deposition C4d on Platelets Is Associated with Vascular Events in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 682

Correlation Between the Lupus Foundation of America – Rapid Evaluation of Activity in Lupus (LFA-REAL) Patient Reported Outcome (PRO) and Health-Related Quality of Life (HRQoL) and Other PROs in a Primarily Mestizo Population

9:00AM-11:00AM: Abstract Number: 692

Correlation of Urinary Soluble CD163 Levels with Clinicopathological Features in Lupus Nephritis: Its Role as a Potential Biomarker

9:00AM-11:00AM: Abstract Number: 644

Decreased HVEM Expression in Lupus Patients and Impact of HVEM Knockout Mouse Model of Lupus Suggest a Role for BTLA Signaling in Disease Pathogenesis

9:00AM-11:00AM: Abstract Number: 697

Differing Opinions on Clinical Research Between Healthcare Providers and Lupus Patients

9:00AM-11:00AM: Abstract Number: 659

Diminished Memory B-cells in Systemic Lupus Erythematosus Patients with Low Disease Activity

9:00AM-11:00AM: Abstract Number: 658

Disentangling Connective Tissue Diseases: Overlaps and Disparities in Clinical Diagnosis, Classification Criteria and Autoantibodies – Results from the Lupus Extended Autoimmune Phenotype Study

9:00AM-11:00AM: Abstract Number: 640

Elevated Serum Interleukin-23 Level in Patients with Systemic Lupus Erythematosus Is Associated with Disease Activity, Clinical and Immunological Markers

9:00AM-11:00AM: Abstract Number: 695

Environmental and Atmospheric Factors in Systemic Lupus Erythematosus: A Regression Analysis

9:00AM-11:00AM: Abstract Number: 681

Evaluation of the Lupus Foundation of America – Rapid Evaluation of Activity in Lupus (LFA-REAL) Clinician Reported Outcome (ClinRO) and Patient Reported Outcome (PRO) in a Primarily Mestizo Population

9:00AM-11:00AM: Abstract Number: 693

Hair Chemicals and Systemic Lupus Erythematosus: A Case-Control Study

9:00AM-11:00AM: Abstract Number: 637

How Often Should SLE Patients Be Tested for Lupus Anticoagulant?

9:00AM-11:00AM: Abstract Number: 704

Improving Patient-Centered Care by Utilizing Lupus Wellness Program

9:00AM-11:00AM: Abstract Number: 647

Is ANA-status at Disease Inception Associated with Long-term Damage Accrual and Direct and Indirect Health Care Costs in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort?

9:00AM-11:00AM: Abstract Number: 668

Lack of Uptake of Prophylactic Human Papilloma Virus (HPV) Vaccination Among Women with Systemic Lupus Erythematosus (SLE) in the Detroit, MI Area, a High Risk Population

9:00AM-11:00AM: Abstract Number: 679

Longitudinal Changes in Manifestations of SLE

9:00AM-11:00AM: Abstract Number: 638

Longitudinal Trends for Estimated Glomerular Filtration Rate and Predictors of Change in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 698

Measurement of Type I IFNα Production at the mRNA Level and Its Potential Use as a Biomarker in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 672

Mouse SLE Studies Do Not Describe Human SLE

9:00AM-11:00AM: Abstract Number: 664

Myxovirus Resistance Protein a Is a Useful Additional Histological Marker for Cutaneous Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 685

Neutrophil Lymphocyte Ratio as a Marker for Immune Complex-Driven Inflammation in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 653

Newly Diagnosed Lupus Nephritis in Elderly Predicts Good Renal Outcome: A Distinct Disease Subset from Young-onset Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 648

Patients of African Descent Score Higher on Quality of Life Indices Despite Their Known Disease Severity

9:00AM-11:00AM: Abstract Number: 680

Patients Who Do Not Fulfill the 2018 EULAR/ACR Criteria for Systemic Lupus Erythematosus Accrue Less Damage: Data from a Multicenter, Multiethnic US Cohort

9:00AM-11:00AM: Abstract Number: 689

Patterns of High Disease Activity Status and Outcomes in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 677

Performance of Montreal Cognitive Assessment (MoCA) in Screening for Cognitive Impairment in Patients with Lupus Compared to the Neuropsychological Battery

9:00AM-11:00AM: Abstract Number: 657

Performance of the “Do You Know What I Mean” Questionnaire in the Assessment of Disease Knowledge in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 678

Performance of the EULAR/ACR 2019 Classification Criteria for Systemic Lupus Erythematosus in Men, Diverse Ethnicities, and Early Disease

9:00AM-11:00AM: Abstract Number: 650

Performance of the Proposed American College of Rheumatology/European League Against Rheumatism Classification Criteria for Systemic Lupus Erythematosus in Korean Patients

9:00AM-11:00AM: Abstract Number: 663

Peripheral Blood Toll Like Receptor 7 Expression and Serum Interferon Lambda 1 Levels in Systemic Lupus Erythematosus and Their Relation to Disease Activity and Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 671

Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results from an International, Inception Cohort Study

9:00AM-11:00AM: Abstract Number: 649

Potentially Reversible Associations with Fatigue in SLE Patients – Results from a Single-centre Study

9:00AM-11:00AM: Abstract Number: 651

Predictors of Renal Damage in Systemic Lupus Erythematosus Patients from Latin America

9:00AM-11:00AM: Abstract Number: 703

Prior Knowledge Feature Reduction Improves Performance in a Machine Learning Model of Systemic Lupus Erythematosus Flare Status Using Serum Proteomics

9:00AM-11:00AM: Abstract Number: 699

Revising the SLEDAI-2K to Include Additional Constitutional Symptoms to More Accurately Assess Lupus Disease Activity

9:00AM-11:00AM: Abstract Number: 702

Seasonality of Cutaneous and Systemic Flares in Adults and Children in the Einstein Lupus Cohort

9:00AM-11:00AM: Abstract Number: 666

Sensitivity to Change of the Patient Reported Outcomes Measurement Information System (PROMIS) Computerized Adaptive Test (CAT) Measures in a Single Canadian Lupus Cohort

9:00AM-11:00AM: Abstract Number: 656

Serum Albumin as a Long-term Predictor of Renal Evolution in Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 700

Sleep Quality Among Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 696

The Performance of a Renal Activity Index in Lupus Nephritis in Induction Therapy

9:00AM-11:00AM: Abstract Number: 667

The PROMIS-29 as a Measure of Type 1 and 2 SLE Activity

9:00AM-11:00AM: Abstract Number: 690

Urinary MRP8/14, an Endogenous Toll-Like Receptor 4 Ligand, Reflects Renal Disease Activity in Lupus Nephritis: A Cross-Sectional and Longitudinal Assessment

9:00AM-11:00AM: Abstract Number: 662

Utility of a Mobile Phone Based Application to Collect Patient-Reported Outcome Information from People Living with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 665

Utility of Repeat Renal Biopsies in Patients with Lupus Nephritis in Western Australia

9:00AM-11:00AM: Abstract Number: 636

Validation and Transcultural Adaptation of the Spanish Version of Brief Index of Lupus Damage (BILD) Questionnaire

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].